Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate

Journal of Bone and Joint Surgery - Series B

Volumn 93 B, Issue 8, 2011, Pages 1134-1139

  Schindeler, A ^a   Birke, O ^a   Yu, N Y C ^a   Morse, A ^a   Ruys, A ^b   Baldock, P A ^c   Little, D G ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; NEUROFIBROMIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CALLUS; CONTROLLED STUDY; DISTAL TIBIA FRACTURE; FRACTURE HEALING; HISTOPATHOLOGY; MOUSE; NONHUMAN; OPEN FRACTURE; OSTEOLYSIS; OUTCOME ASSESSMENT; PERIOSTEUM; POSTOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEIN 2; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FRACTURE FIXATION, INTERNAL; FRACTURE HEALING; FRACTURES, UNUNITED; IMIDAZOLES; MICE; MICE, KNOCKOUT; NEUROFIBROMATOSIS 1; POSTOPERATIVE CARE; PSEUDARTHROSIS; RECOMBINANT PROTEINS; TIBIAL FRACTURES; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 79960638924     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.93B8.25940     Document Type: Article

References (35)

1. Hefti F, Bollini G, Dungl P, et al. Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B 2000;9:11-15. (Pubitemid 30044014)
2. Traub JA, O'Connor W, Masso PD. Congenital pseudarthrosis of the tibia: a retrospective review. J Pediatr Orthop 1999;19:735-8.
3. Yu X, Chen S, Potter OL, et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005;36:793-802. (Pubitemid 40616014)
4. Yang FC, Chen S, Robling AG, et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006;116:2880-91. (Pubitemid 44684473)
5. Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 2008;42:616-22.
6. Boero S, Catagni M, Donzelli O, Facchini R, Frediani PV. Congenital pseudarthrosis of the tibia associated with neurofibromatosis-1: treatment with Ilizarov's device. J Pediatr Orthop 1997;17:675-84. (Pubitemid 28048756)
7. Ghanem I, Damsin JP, Carlioz H. Ilizarov technique in the treatment of congenital pseudarthrosis of the tibia. J Pediatr Orthop 1997;17:685-90. (Pubitemid 28048757)
8. Plawecki S, Carpentier E, Lascombes P, Prevot J, Robb JE. Treatment of congenital pseudarthrosis of the tibia by the Ilizarov method. J Pediatr Orthop 1990;10:786-90. (Pubitemid 20368672)
9. Anderson DJ, Schoenecker PL, Sheridan JJ, Rich MM. Use of an intramedullary rod for the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg [Am] 1992;74-A:161-8.
10. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker PL. Use of an intramedullary rod for treatment of congenital pseudarthrosis of the tibia: a long-term follow-up study. J Bone Joint Surg [Am] 2004;86-A:1186-97. (Pubitemid 38724881)
11. Mathieu L, Vialle R, Thevenin-Lemoine C, Mary P, Damsin JP. Association of Ilizarov's technique and intramedullary rodding in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 2008;2:449-55.
12. Grill F, Bollini G, Dungl P, et al. Treatment approaches for congenital pseudarthrosis of tibia: results of the EPOS multicenter study: European Paediatric Orthopaedic Society (EPOS). J Pediatr Orthop B 2000;9:75-89. (Pubitemid 30253772)
13. Ofluoglu O, Davidson RS, Dormans JP. Prophylactic bypass grafting and long-term bracing in the management of anterolateral bowing of the tibia and neurofibromatosis-1. J Bone Joint Surg [Am] 2008;90-A:2126-34.
14. Joseph B, Somaraju VV, Shetty SK. Management of congenital pseudarthrosis of the tibia in children under 3 years of age: effect of early surgery on union of the pseudarthrosis and growth of the limb. J Pediatr Orthop 2003;23:740-6. (Pubitemid 37323060)
15. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg [Am] 2002;84-A:2123-34. (Pubitemid 35417689)
16. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg [Am] 2001;83-A(Suppl 1, Pt 2):151-8.
17. Anticevic D, Jelic M, Vukicevic S. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report. J Pediatr Orthop B 2006;15:220-1.
18. Lee FY, Sinicropi SM, Lee FS, et al. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7): a report of five cases. J Bone Joint Surg [Am] 2006;88-A:627-33.
19. Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delince P. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg [Br] 2006;88-B:116-18. (Pubitemid 43125326)
20. Richards BS, Oetgen ME, Johnston CE. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg [Am] 2010;92- A:177-85.
21. Schindeler A, Ramachandran M, Godfrey C, et al. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res 2008;26:65-74.
22. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005;20:2044-52 (Pubitemid 41532790)
23. Schindeler A, Morse A, Harry L, et al. Models of tibial fracture healing in normal and Nf1-deficient mice. J Orthop Res 2008;26:1053-60.
24. Jensen ED, Pham L, Billington CJ Jr, et al. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010;109:672-82.
25. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-29. (Pubitemid 24145666)
26. Stevenson DA, Zhou H, Ashrafi S, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006;79:143-8. (Pubitemid 43927385)
27. Leskela HV, Kuorilehto T, Risteli J, et al. Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression. Bone 2009;44:243-50.
28. Joseph B, Mathew G. Management of congenital pseudarthrosis of the tibia by excision of the pseudarthrosis, onlay grafting, and intramedullary nailing. J Pediatr Orthop B 2000;9:16-23. (Pubitemid 30044015)
29. Steib JP, Bouchaib J, Walter A, Schuller S, Charles YP. Could an osteoinductor result in degeneration of a neurofibroma in NF1? Eur Spine J 2010;19(Suppl 2):220-5.
30. Kaneko H, Arakawa T, Mano H, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000;27:479-86.
31. Li H, Liu Y, Zhang Q, et al. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr Res 2009;65:613-18.
32. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006;91:511-16. (Pubitemid 43236917)
33. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005;20:1235-43. (Pubitemid 40863813)
34. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. (Pubitemid 40463979)
35. Birke O, Schindeler A, Ramachandran M, et al. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 2010;4:507-17.